Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Minocycline foam - Journey Medical Corporation

Next Previous
X
Search
Drug Profile

Minocycline foam - Journey Medical Corporation

Alternative Names: AMZEEQ; AMZEEQ topical foam; FMX 102; FMX 103; FMX-101; FXFM-244; Minocycline foam, 1.5%; Minocycline foam, 4%; ZILXI

Latest Information Update: 09 Oct 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Foamix
  • Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Dimethylamines; Eye disorder therapies; Neuroprotectants; Skin disorder therapies; Small molecules; Tetracyclines
  • Mechanism of Action Glial cell inhibitors; Interleukin 1 alpha inhibitors; Interleukin 6 modulators; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acne vulgaris; Rosacea
  • Phase II Impetigo

Most Recent Events

  • 14 Jan 2022 Journey Medical Corporation purchases Minocycline foam from VYNE Therapeutics
  • 12 Aug 2021 Minocycline foam - Foamix is available for licensing as of 12 Aug 2021. www.vynetherapeutics.com
  • 09 Aug 2021 VYNE Therapeutics initiates litigation against Padagis Israel Pharmaceuticals over ANDA submission in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top